JonesTrading Begins Coverage on Vogenx (NASDAQ:VOGX)

JonesTrading initiated coverage on shares of Vogenx (NASDAQ:VOGX) in a research report issued on Tuesday, Benzinga reports. The firm set a “buy” rating and a $55.00 price target on the stock. JonesTrading’s target price suggests a potential upside of 64.13% from the company’s previous close.

Separately, Wall Street Zen upgraded Vogenx to a “hold” rating in a research note on Saturday, August 22nd. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $55.00.

Vogenx Price Performance

NASDAQ:VOGX traded down $0.49 during mid-day trading on Tuesday, reaching $33.51. The stock had a trading volume of 293,573 shares, compared to its average volume of 240,271. Vogenx has a 12 month low of $12.95 and a 12 month high of $35.50.

About Vogenx

Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.